Recipham invests €32m to expand lyophilisation capacity in Germany

To build new production building with large scale freeze drying capability at Wasserburg

Recipharm is expanding its lyophilisation capacity in Wasserburg, Germany

Swedish drugmaker Recipharm is to invest €32m at its Wasserburg plant near Munich in Germany to increase its freeze-drying capacity.

The firm will construct a new building to house a fourth production area, adding to the three already in operation. This new state-of-the-art facility will be equipped with the latest automatic loading and unloading technology. The building will also have the flexibility to accommodate further production lines.

Recipharm will add around 40 new members of staff to the current 282 and the new area is expected to be operational in 2016.

The Wasserburg facility, established nearly 40 years ago, has a long history of filling vials and ampoules for large, medium and small pharmaceutical companies. It has emerged as a leading specialist in aseptic filling and lyophilisation of injectable drugs, supplying Europe, the US, Brazil and Asia Pacific.

Armin Dalluege: We see this investment as vital to maintain and increase our leadership in this field

'We have been operating at full capacity for several years now and we see this investment as vital to maintain and increase our leadership in this field. Demand for lyophilisation is expected to increase in the coming years and we intend to be at the forefront of servicing this,' said Armin Dallüge, General Manager of Recipharm in Wasserburg.

Thomas Eldered, CEO of Recipharm, added: 'Given the excellent track record of Wasserburg and in particular the highly skilled workforce, we are very confident that this investment will help us to consolidate our position as one of the world’s leading CDMOs.'